



To whom it may concern

Dr. Stefan Dreiheller
Quality Unit / Regulatory Affairs

Date of issue: 11.02.2021
Page 1/1
Doc.-No. EIP-0063
Revision 10

Preparation of Documents

MEGGLE Products:

- Lactose Monohydrate (Ph. Eur. / USP-NF / JP): CapsuLac[®] 60, FlowLac[®] 90, FlowLac[®] 100, GranuLac[®] 70, GranuLac[®] 80, GranuLac[®] 140, GranuLac[®] 200, GranuLac[®] 230, PrismaLac[®] 40, SacheLac[®] 80, SorboLac[®] 400, SpheroLac[®] 100, Tablettose[®] 70, Tablettose[®] 80, Tablettose[®] 100
- Lactose Monohydrate (USP-NF / Ph. Eur. / JP): Lactose monohydrate Low Endotoxin
- Inhaler Grade Lactose Monohydrate (USP-NF / Ph. Eur. / JP): InhaLac[®] 70, InhaLac[®] 120, InhaLac[®] 140, InhaLac[®] 150, InhaLac[®] 160, InhaLac[®] 230, InhaLac[®] 250, InhaLac[®] 251, InhaLac[®] 400, InhaLac[®] 500
- Co-processed excipients: Cellactose[®] 80, CombiLac[®], MicroceLac[®] 100, RetaLac[®], Reta M[®], StarLac[®]

MEGGLE specifications are generated within a validated document management system.

Check and approval of documents is conducted via electronic signature. Electronic signature meets the requirements of 21 CFR Part 11.

Product release is conducted and the issue of CoA's are generated within a validated ERP system

Best regards

MEGGLE GmbH & Co. KG

represented by MEGGLE Verwaltungs GmbH


Dr. Stefan Dreiheller